{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:59:13Z","timestamp":1794340753900,"version":"4.9.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12\u2009mg, 24\u2009mg, 36\u2009mg, and 45\u2009mg, with nausea being the most common side effect in all groups. For the 45\u2009mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90\u20136.71), while the 36\u2009mg dose had an OR of 3.99 (95% CI: 2.22\u20137.18). The OR for the 24\u2009mg dose was 5.66 (95% CI: 3.39\u20139.45), and the 12\u2009mg dose showed an OR of 5.06 (95% CI: 3.31\u20137.73). Oral danuglipron at doses of 80\u2009mg and 120\u2009mg were also studied. The 120\u2009mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30\u20138.34) while the 80\u2009mg dose had an OR of 3.69 (95% CI: 1.77\u20137.67) indicating a significant decrease in gastrointestinal side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo\/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046671","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T21:00:53Z","timestamp":1766782853000},"page":"e46671","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Himal Bikram","family":"Bhattarai","sequence":"first","affiliation":[{"name":"Department of Medicine, Dubai London Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basanta Sharma","family":"Paudel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tribhuvan University, Institute of Medicine, Maharajgunj, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh Raman","family":"Parajuli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Reading Hospital, West Reading, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Dahal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tribhuvan University, Institute of Medicine, Maharajgunj, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8203-3329","authenticated-orcid":false,"given":"Sangam","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tribhuvan University, Institute of Medicine, Maharajgunj, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-1082","authenticated-orcid":false,"given":"Madhur","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tribhuvan University, Institute of Medicine, Maharajgunj, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidisha","family":"Baral","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ascension Saint Agnes Hospital, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibek","family":"Karki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hurley Medical Center, Michigan State University, Flint, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhusan","family":"Basnet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Frye Regional Medical Center, Hickory, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Department of Medicine, St. John\u2019s Hospital, Springfield, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sah","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India"},{"name":"Department of Medicine, BMC South, BMC Health System, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khanal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hurley Medical Center, Michigan State University, Flint, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McDonald","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hurley Medical Center, Michigan State University, Flint, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251226","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 based therapies: clinical implications for gastroenterologists.","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"key":"R2-20251226","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus.","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"R3-20251226","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12576-017-0581-5","article-title":"Effects of exergaming on cardiovascular risk factors and adipokine levels in women.","volume":"68","author":"Amorim","year":"2018","journal-title":"J Physiol Sci"},{"key":"R4-20251226","article-title":"Glucagon-Like Peptide 1 Secretion by the L-Cell.","author":"Lim","journal-title":"Diabetes"},{"key":"R5-20251226","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial.","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"R6-20251226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dom.12175","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R7-20251226","doi-asserted-by":"crossref","first-page":"155710","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"key":"R8-20251226","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R9-20251226","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20251226","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R11-20251226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R12-20251226","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R13-20251226","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity.","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"R14-20251226","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"R15-20251226","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, phase 2 study comparing different dose-escalation schemes.","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R16-20251226","doi-asserted-by":"crossref","first-page":"e2314493","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial.","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R17-20251226","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74\u2009mg with once-weekly semaglutide 2\u00b74\u2009mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"R18-20251226","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus.","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"R19-20251226","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":"Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.","volume":"96","author":"Buse","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20251226","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"key":"R21-20251226","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art.","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R22-20251226","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity.","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"R23-20251226","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"R24-20251226","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R25-20251226","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s40265-017-0783-4","article-title":"Insulin glargine\/lixisenatide: a review in type 2 diabetes.","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"R26-20251226","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"R27-20251226","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes.","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"R28-20251226","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:23:53Z","timestamp":1785857033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":28,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046671","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-09-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}